Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic.
about
Characterization of MDL 73005EF as a 5-HT1A selective ligand and its effects in animal models of anxiety: comparison with buspirone, 8-OH-DPAT and diazepamFlibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxietyEquine metabolism of buspirone studied by high-performance liquid chromatography/mass spectrometryPhasic and sustained fear are pharmacologically dissociable in rats.Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs.The 5-HT1A receptor and the stimulus effects of LSD in the rat.Discriminative stimulus effects of diazepam and buspirone in normal volunteers.Pharmacodynamic effects of buspirone and clobazamExperimental animal models for the simulation of depression and anxiety.Pharmacotherapy of alcohol use disorders: seventy-five years of progressAnxiolytic-like actions of buspirone in a runway model of intravenous cocaine self-administration.Concentrations and effects of buspirone are considerably reduced by rifampicinPsychopharmacological characterisation of the successive negative contrast effect in ratsEffects of buspirone on the immediate positive and delayed negative properties of intravenous cocaine as measured in the conditioned place preference testBuspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomized placebo-controlled URCC CCOP study.New drugs. Hypnotics and anxiolyticsSelective serotonin reuptake inhibitors in the treatment of generalized anxiety disorder.Considerations in using psychotropic medication with dual diagnosis patients in recovery.Buspirone: an update on a unique anxiolytic agent.Pharmacotherapy and the neurobehavioural sequelae of traumatic brain injury.Geriatric psychopharmacology. A primary care challenge.Altered serotonergic activity in women with dysphoric premenstrual syndromes.Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine.Evaluation of buspirone on streptozotocin induced type 1 diabetes and its associated complications.The antagonism of benzodiazepine withdrawal effects by the selective cholecystokininB receptor antagonist CI-988.Role of Hypothalamic-pituitary-adrenal-axis in Affective Disorders: Anti-depressant and Anxiolytic Activity of Partial 5-HT1A Agonist in Adrenalectomised Rats.The profiles of interaction of yohimbine with anxiolytic and putative anxiolytic agents to modify 5-HT release in the frontal cortex of freely-moving rats.Drug-induced defaecation in rats: role of central 5-HT1A receptors.Cholecystokinin release mediated by 5-HT3 receptors in rat cerebral cortex and nucleus accumbensPharmacokinetics of buspirone extended-release tablets: a single-dose study.A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product.CNS effects of sumatriptan and rizatriptan in healthy female volunteers.Buspirone and agitation in head injury.Pharmacokinetic interaction between tandospirone and fluvoxamine in the rat contextual conditioned fear stress model and its functional consequence: Involvement of cytochrome P450 3A4.In vitro metabolism of the antianxiety drug buspirone as a predictor of its metabolism in vivo.New imide 5-HT1A receptor ligands - modification of terminal fragment geometry.Comparison of buspirone with diazepam and fluvoxamine on aversive classical conditioning in humans.The ligand-binding site of buspirone analogues at the 5-HT1A receptor.
P2860
Q24673597-FFA4DBEC-5216-4A1B-9853-CFD724CF5F0BQ24675009-735734BE-127E-49BF-A95A-6E14A2925D0BQ28376926-9BB3E2E2-E652-47AC-A369-97B1B3295538Q30466236-546407D4-0391-49FB-9FDE-D9053642C469Q34024109-A2221963-B382-454E-913A-2CB7E00A9911Q34099158-89415899-A666-44F9-9BA9-CB8956BF5A17Q34270192-B41ECC8E-B5B1-4740-B99B-A04F5269CDFDQ34358579-422A8DD0-E1BE-4A70-A8F8-8A03A0BAB6BEQ35236855-8D985B16-50D3-4253-A2E6-0D317340A9B4Q35677411-03185729-2CC6-4C27-BAEE-77759DCD6238Q35750410-BE89405A-F242-40E0-B196-57000D7E3880Q35802991-25BEF35A-D2C5-4D34-8BC2-14374C1C74E1Q35851639-7F96414A-B0BE-4A13-8477-0FFA23AF51B6Q35942229-15BEAA71-1DB9-49EF-A9EA-C1745E511548Q36249079-E6F6D4A7-F337-403B-B9FF-4C769B328744Q36515444-1AE5D4AE-2D5E-4313-8E4E-AB40BFC9BDC1Q37582752-B1B15E6E-00D8-4190-A374-7E500EF133CAQ37610268-4ED18502-19E1-4961-A3FC-CE2274B10B5DQ38674029-62A8CB02-1ED1-4847-8A69-0A63E5280640Q39511776-52351CA2-DCC0-4D1C-8894-E07B4819EBADQ39524746-19847434-8DE3-4155-B48C-1C3C0DE420A4Q40882817-AB99A83E-D657-44CD-8C0F-91DBFD131908Q40918717-2099841A-39E2-4BF0-8CDB-CF83122CA130Q41872669-DDC3DE66-D0A3-419B-9816-BE47158850A6Q41921965-76C0630E-DC9A-49E7-AFAE-EFF0069EA6D4Q42003959-510F3891-3865-4E89-A6A2-A346439AB8C9Q42118191-CE156575-C4F6-4F04-8E3B-9E2E3DA67A94Q42141250-12CEECAF-F24B-4523-9505-7C2B0A301CBBQ42709755-91E6A1E8-8619-4C73-AEB5-9FB28719CF17Q42716106-DE92EA57-9402-4355-87D3-381F2AC2586EQ43673477-CBDA5488-273F-4765-8F80-3BA3E40927A0Q43706453-C47DF019-9BFD-4D68-B2EE-9E26FFDB9927Q44051817-165D7829-CC5E-497A-A855-C6E5B1D2F934Q44547831-A132173C-EBDC-4D86-A04A-1711C1748CFFQ46298123-22FC2D2A-E4C1-46AD-BCE1-AF820CF75B34Q46354190-5075D9E2-9B2A-4932-B4DC-C841108CA9A1Q46896923-065C7076-C659-4504-8520-1DB7C7A884F0Q51442262-41CDF316-855C-4460-8177-148E6136646AQ54364786-2E2956DD-A00A-4623-AED9-E3D8204110B2
P2860
Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
Buspirone. A preliminary revie ...... tic efficacy as an anxiolytic.
@en
Buspirone. A preliminary revie ...... tic efficacy as an anxiolytic.
@nl
type
label
Buspirone. A preliminary revie ...... tic efficacy as an anxiolytic.
@en
Buspirone. A preliminary revie ...... tic efficacy as an anxiolytic.
@nl
prefLabel
Buspirone. A preliminary revie ...... tic efficacy as an anxiolytic.
@en
Buspirone. A preliminary revie ...... tic efficacy as an anxiolytic.
@nl
P1433
P1476
Buspirone. A preliminary revie ...... tic efficacy as an anxiolytic.
@en
P304
P356
10.2165/00003495-198632020-00002
P577
1986-08-01T00:00:00Z
P6179
1030918482